CAR T-cells as Third-line and Beyond Therapy for FL
Bijal Shah, MD, discusses recent data on CAR T-cell therapy as third-line and beyond treatment for FL.
Stay updated with breaking news from Liso Cel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Bijal Shah, MD, discusses recent data on CAR T-cell therapy as third-line and beyond treatment for FL.
Alexey Danilov, MD, PhD, reviews data from the TRANSCEND NHL 001 study investigating lisocabtagene maraleucel in patients with relapsed/refractory mantle cell lymphoma.
The FDA has granted priority review to the supplemental biologics license application seeking approval to expand the indication of lisocabtagene maraleucel to include patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who had prior exposure to a BTK inhibitor and a BCL-2 inhibitor.
Dr Gordon discusses use of bispecifics for management of patients with relapsing DLBCL.
Treatment of DLBCL amid comorbidities in elderly patients is highlighted.